2. PROTAC Autophagy Apoptosis
  3. Molecular Glues Ligands for E3 Ligase Autophagy Apoptosis
  4. (S)-Thalidomide

(S)-Thalidomide  (Synonyms: (S)-(-)-Thalidomide)

Cat. No.: HY-14658A Purity: 99.65%
COA Handling Instructions

Molarity Calculator

(S)-Thalidomide ((S)-(-)-Thalidomide) is the S-enantiomer of Thalidomide. (S)-Thalidomide has immunomodulatory, anti-inflammatory, antiangiogenic and pro-apoptotic effects. (S)-Thalidomide induces teratogenic effects by binding to cereblon (CRBN) .

For research use only. We do not sell to patients.

(S)-Thalidomide Chemical Structure

(S)-Thalidomide Chemical Structure

CAS No. : 841-67-8

Size Price Stock Quantity
5 mg USD 70 In-stock
10 mg USD 110 In-stock
25 mg USD 240 In-stock
50 mg USD 380 In-stock
100 mg USD 680 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of (S)-Thalidomide:

(S)-Thalidomide Related Antibodies

Top Publications Citing Use of Products

View All Ligands for E3 Ligase Isoform Specific Products:

View All Isoforms
von Hippel-Lindau (VHL) MDM2 Cereblon IAP

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

(S)-Thalidomide ((S)-(-)-Thalidomide) is the S-enantiomer of Thalidomide. (S)-Thalidomide has immunomodulatory, anti-inflammatory, antiangiogenic and pro-apoptotic effects[1][2][3]. (S)-Thalidomide induces teratogenic effects by binding to cereblon (CRBN) [4].

IC50 & Target

Cereblon

 

In Vitro

(S)-Thalidomide treatment results in a reduction in cell viability in U266 cells with an IC50 of 362 μM[1].
(S)-Thalidomide treatment increased apoptosis in a dose-dependent manner in U266 cells[1].
There are changes in the expression profile of genes involved in angiogenesis and apoptosis, but the changes are most dramatic in the apoptotic genes. In particular, the expression of I-κB kinase is decreased by two-fold, which is associated with a four-fold decrease in NF-κB expression. (S)-Thalidomide increases the Bax:Bcl-2 ratio, also increases I-kB protein levels, and decreases NF-kB activity. A dramatic decrease in Bcl-2 expression with (S)-Thalidomide suggests a possible enhancement of cytotoxic effect if combined with other cytotoxic agents[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

(S)-Thalidomide Related Antibodies

Cell Viability Assay[1]

Cell Line: U266 MM cells
Concentration: 0 µM, 10 µM, 100 µM, 150 µM, 200 µM, 1000 µM
Incubation Time: 3 days
Result: A reduction in cell viability was observed in U266 cells.

Apoptosis Analysis[1]

Cell Line: U266 MM cells
Concentration: 100 µM, 150 µM, 200 µM, 1000 µM
Incubation Time: 3 days
Result: Increased apoptosis in U266 cells.
In Vivo

Thalidomide does cause limb reduction defects in chick embryos as long as the embryos are directly exposed to the drug. The most useful techniques are implanting Thalidomide-soaked beads into the embryo immediately adjacent to the limb territory or soaking presumptive chick limb territories in Thalidomide and then grafting the explants to a host embryo celom. Thalidomide affects the chick limb grafted to a host embryo in a dose response fashion. Furthermore, (S)-Thalidomide is more teratogenic than (R)-Thalidomide[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

258.23

Formula

C13H10N2O4
CAS No.
Appearance

Solid

Color

Off-white to light brown

SMILES

O=C1N([C@@H](CC2)C(NC2=O)=O)C(C3=C1C=CC=C3)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 83.33 mg/mL (322.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.8725 mL 19.3626 mL 38.7252 mL
5 mM 0.7745 mL 3.8725 mL 7.7450 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 99.65%

COA (252 KB) HNMR (244 KB) LCMS (259 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.8725 mL 19.3626 mL 38.7252 mL 96.8129 mL
5 mM 0.7745 mL 3.8725 mL 7.7450 mL 19.3626 mL
10 mM 0.3873 mL 1.9363 mL 3.8725 mL 9.6813 mL
15 mM 0.2582 mL 1.2908 mL 2.5817 mL 6.4542 mL
20 mM 0.1936 mL 0.9681 mL 1.9363 mL 4.8406 mL
25 mM 0.1549 mL 0.7745 mL 1.5490 mL 3.8725 mL
30 mM 0.1291 mL 0.6454 mL 1.2908 mL 3.2271 mL
40 mM 0.0968 mL 0.4841 mL 0.9681 mL 2.4203 mL
50 mM 0.0775 mL 0.3873 mL 0.7745 mL 1.9363 mL
60 mM 0.0645 mL 0.3227 mL 0.6454 mL 1.6135 mL
80 mM 0.0484 mL 0.2420 mL 0.4841 mL 1.2102 mL
100 mM 0.0387 mL 0.1936 mL 0.3873 mL 0.9681 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

(S)-Thalidomide Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(S)-Thalidomide841-67-8(S)-(-)-ThalidomideMolecular GluesLigands for E3 LigaseAutophagyApoptosisE3 ligase-recruiting MoietyAnti-angiogenicracemateanti-tumourenantiomersintravenously immunomodulatoryteratogenicanti-inflammatoryInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
(S)-Thalidomide
Cat. No.:
HY-14658A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.